EUVIMEDEUVIMED entdecken
Open Access

A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial

Giuseppe Tarantini, Peter Cornelius Smits, Thibault Lhermusier, Benjamin Honton, Grégoire Rangé, Christophe Piot, Gilles Lemesle, Juan Miguel Ruiz Nodar, Matthieu Godin, Maria Madera Cambero, Pascal Motreff, Thomas Cuisset und 3 weitere

EuroIntervention · 2023

DOI: 10.4244/eij-d-22-01006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EuroIntervention, 2023. Verfasst von Giuseppe Tarantini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Based on the latest knowledge and technological advancements, it is still debatable whether a modern revascularisation approach in the setting of acute myocardial infarction (AMI), including complete revascularisation (in patients with significant non-culprit lesions) with newer-generation highly biocompatible drug-eluting stents, requires prolonged dual antiplatelet therapy (DAPT). TARGET-FIRST (ClinicalTrials.gov: NCT04753749) is a prospective, open-label, multicentre, randomised controlled study comparing short (one month) DAPT versus standard (12 months) DAPT in a population of patients with non-ST/ST-segment elevation myocardial infarction, completely revascularised at index or staged procedure (within 7 days), using Firehawk, an abluminal in-groove biodegradable polymer rapamycin-eluting stent. The study will be conducted at approximately 50 sites in Europe. After a mandatory 30-40 days of DAPT with aspirin and P2Y12 inhibitors (preferably potent P2Y12 inhibitors), patients are randomised (1:1) to 1) immediate discontinuation of DAPT followed by P2Y12 inhibitor monotherapy (experimental arm), or 2) continued DAPT with the same regimen (control arm), up until 12 months. With a final sample size of 2,246 patients, the study is powered to evaluate the primary endpoint (non-inferiority of short antiplatelet therapy in completely revascularised patients) for net adverse clinical and cerebral events. If the primary endpoint is met, the study is powered to assess the main secondary endpoint (superiority of short DAPT in terms of major or clinically relevant non-major bleeding). TARGET-FIRST is the first randomised clinical trial to investigate the optimisation of antiplatelet therapy in patients with AMI after achieving complete revascularisation with an abluminal in-groove biodegradable polymer rapamycin-eluting stent implantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Eluting StentsMyocardial InfarctionPercutaneous Coronary InterventionHumansPlatelet Aggregation InhibitorsProspective StudiesSirolimusPolymersTreatment OutcomeMulticenter Studies as TopicRandomized Controlled Trials as TopicEquivalence Trials as Topic

Substanzen

Platelet Aggregation InhibitorsSirolimusPolymers

Autor:innen und Institutionen

  • Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
  • Maasstad Ziekenhuis, Rotterdam, the Netherlands.
  • CHU de Toulouse, Pôle Cardiovasculaire et Métabolique, Toulouse, France.
  • Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France.
  • Service de Cardiologie, Centre Hospitalier de Chartres, Hôpital Louis Pasteur, Le Coudray, France.
  • Service/Pôle de Cardiologie, Clinique du Millénaire, Montpellier, France.

Zitieren

APA

Tarantini, G., Smits, P. C., Lhermusier, T., Honton, B., Rangé, G., Piot, C., Lemesle, G., Ruiz Nodar, J. M., Godin, M., Madera Cambero, M., Motreff, P., Cuisset, T., Bouchez, D., Poezevara, Y., & Cayla, G. (2023). A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial. EuroIntervention. https://doi.org/10.4244/eij-d-22-01006

Vancouver

Tarantini G, Smits PC, Lhermusier T, Honton B, Rangé G, Piot C, et al. A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial. EuroIntervention. 2023. doi:10.4244/eij-d-22-01006

BibTeX
@article{Tarantini2023,
  author = {Tarantini, Giuseppe and Smits, Peter Cornelius and Lhermusier, Thibault and Honton, Benjamin and Rangé, Grégoire and Piot, Christophe and Lemesle, Gilles and Ruiz Nodar, Juan Miguel and Godin, Matthieu and Madera Cambero, Maria and Motreff, Pascal and Cuisset, Thomas and Bouchez, David and Poezevara, Yann and Cayla, Guillaume},
  title = {A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial},
  journal = {EuroIntervention},
  year = {2023},
  doi = {10.4244/eij-d-22-01006}
}
Kostenlos starten →